ClinicalTrials.gg
CompletedNCT03559699Updated Jan 4, 2022Results posted

A Study Evaluating the Efficacy and Safety of AG-348 in Regularly Transfused Adult Participants With Pyruvate Kinase Deficiency (PKD)

A Phase 3 interventional study of AG-348 in Pyruvate Kinase Deficiency and Anemia, Hemolytic, sponsored by Agios Pharmaceuticals, Inc.. Completed at 19 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-01-04.

Sponsored by Agios Pharmaceuticals, Inc. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
27
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 35 studies in Anemia, Hemolytic with a site in United States — 8 open to participants now, 11 under way, 1 of them phase 3. Anemia, Hemolytic · United States.

Enrollment
17th of 26
27 · median 47
Started
2018
with 2 others
Phase 3
4 of 35
none open now
Registered
16th of 35
by date
Lead sponsor
4 of 35
Agios Pharmaceuticals, Inc.

Among the 35 studies in Anemia, Hemolytic with a site in United States, this one is the 17th largest by enrollment of the 26 interventional ones that give a count, is one of 3 that started in 2018, is one of 4 in phase 3, and was the 16th registered.

Anemia, Hemolytic

56 studies on the registry are indexed under Anemia, Hemolytic; 16 are open to participants now.

Browse Anemia, Hemolytic studies →

Open to participants now

8 of the 35 studies in Anemia, Hemolytic with a site in United States are open now. Recruiting first, the newest first:

3 more — sign in →

All 8 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 8 Anemia, Hemolytic studies recruiting now, 3 set no upper age limit and 4 stop at 75 or younger; 6 take children under 18; none take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 35 studies in Anemia, Hemolytic with a site in United States, or all of them as a file.
02

Study summary

Study AG348-C-007 was a multicenter study designed to evaluate the efficacy and safety of treatment with AG-348 in a minimum of 20, with up to 40, participants with pyruvate kinase (PK) deficiency, who were regularly receiving blood transfusions. The study was composed of two parts. During Part 1, Dose Optimization Period, participants started on a dose of 5 mg AG-348 administered twice daily. Over the course of Part 1 each participant's dose of AG-348 was sequentially increased to 20 mg twice a day, followed by 50 mg twice a day depending on their tolerance. During Part 2, Fixed-Dose Period, participants received AG-348 at their optimized dose from Part 1.

03

Conditions studied

  • Pyruvate Kinase Deficiency
  • Anemia, Hemolytic

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • ;
  • Male or female, aged 18 or older;
  • Presence of at least 2 mutant alleles in the Pyruvate Kinase Liver and RBC (PKLR) gene, of which at least 1 is a missense mutation;
  • History of a minimum of 6 transfusion episodes in the 52-week period prior to date of informed consent;
  • Complete records of transfusion history for the 52 weeks prior to the date of informed consent, including all transfusion dates, number of blood units transfused for all the transfusions, and concentrations within 1 week prior to transfusion for at least 80% of the transfusions;
  • Have received at least 0.8 mg of oral folic acid daily for at least 21 days prior to the first dose of study drug, to be continued daily during study participation;
  • Have adequate organ function;
  • Negative serum pregnancy test for women of ;
  • For women of reproductive potential as well as fertile men and their partners who are women of reproductive potential: be abstinent or agree to use 2 forms of , 1 of which must be considered highly effective, from the time of giving informed consent, during the study, and for 28 days following the last dose of AG-348;
  • Willing to comply with all study procedures, in particular the individual transfusion trigger (TT) calculated based on 52 weeks of transfusion history, for the duration of the study.

Exclusion criteria

Exclusion Criteria:

  • Homozygous for the R479H mutation or have 2 non-missense mutations, without the presence of another missense mutation, in the PKLR gene;
  • Significant medical condition that confers an unacceptable risk to participate in the study, and/or that could confound the interpretation of the study data;
  • History of transfusions occurring on average more frequently than once every 3 weeks during the 52 weeks prior to date of ;
  • Splenectomy scheduled during the study treatment period or have undergone splenectomy within 12 months prior to signing informed consent;
  • Currently enrolled in another therapeutic clinical trial. Prior participation in the PK Deficiency Natural History Study (NHS) (NCT02053480) or PK Deficiency Registry is permitted;
  • Exposure to any drug, device, or procedure within 3 months prior to the first dose of study drug;
  • Prior bone marrow or stem cell transplant;
  • Currently pregnant or breastfeeding;
  • History of major surgery within 6 months of signing informed consent;
  • Currently receiving medications that are strong inhibitors of , strong inducers of CYP3A4, strong inhibitors of P-glycoprotein (P-gp), or digoxin (a P-gp sensitive substrate medication) that have not been stopped for a duration of at least 5 days or 5 times their half-lives (whichever is longer) prior to start of study drug;
  • Currently receiving hematopoietic stimulating agents (eg, erythropoietins [EPOs], granulocyte colony stimulating factors, thrombopoietins) that have not been stopped for a duration of at least 28 days prior to the first dose of study drug;
  • History of allergy to sulfonamides if characterized by acute hemolytic anemia, drug induced liver injury, anaphylaxis, rash of erythema multiforme type or Stevens-Johnson syndrome, cholestatic hepatitis or other serious clinical manifestations;
  • Allergy to AG-348 or its ;
  • Currently receiving anabolic steroids, including testosterone preparations, within 28 days prior to the first dose of study drug.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
27 participants (actual)

Study arms

  • Experimental
    AG-348

    Participants received AG-348 tablets, administered orally, at a starting dose of 5 milligrams (mg), twice daily (BID), followed by two sequential dose level increases to 20 mg and 50 mg BID, for a period of 16 weeks in Part 1. This was followed by optimized dose BID, as determined by the investigator in Part 1, for a period of 24 weeks in Part 2.

    Drug: AG-348

Interventions

  • DrugAG-348

    Part 1 (Dose Optimization Period): Participants began by receiving 5 mg orally, BID. Each participant's dose of AG-348 was sequentially increased to 20 mg BID followed by 50 mg BID depending on their response to AG-348 and their tolerance. Part 2 (Fixed Dose Period): Optimized dose determined in Part 1.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Achieving a Reduction in Transfusion Burden in Part 2

    Reduction in transfusion burden is defined as a ≥33% reduction in the number of RBC units transfused during the Fixed Dose Period standardized to 24 weeks compared with the historical transfusion burden standardized to 24 weeks (Standardized Control Period). The on-study (Fixed Dose Period) transfusion burden was calculated as the total number of transfused RBC units received in the Fixed Dose Period standardized to 24 weeks.

    Time frame: From Part 2, Day 1 to Part 2 Week 24

Secondary outcomes

  1. Annualized Number of RBC Units Transfused During the Study

    The annualized total number of RBC units transfused during the entire study (both Part 1 and Part 2) is reported. It was calculated as the total number of RBC units transfused up to the end of Fixed Dose Period divided by the total number of days from the first dose date until the end date of Fixed Dose Period × 52.

    Time frame: Part 1 Day 1 to Part 2 Week 24

  2. Number of Transfusion Episodes in Part 2

    This is the number of transfusion episodes in Part 2. The number of transfusion episodes were standardized to 24 weeks. Transfusions received over up to 3 consecutive days were counted as 1 episode.

    Time frame: From Part 2 Day 1 to Part 2 Week 24

  3. Percentage of Transfusion-Free Participants in Part 2

    Transfusion-free responders were the participants who were transfusion-free in Part 2.

    Time frame: From Part 2 Day 1 to Part 2 Week 24

  4. Percentage of Participants Achieving Normal Hemoglobin (Hb) Concentrations in Part 2

    This is the percentage of participants who achieved hemoglobin (Hb) concentrations in the normal range at least once, 8 weeks or more after a transfusion in Part 2.

    Time frame: From Part 2 Day 1 to Part 2 Week 24

  5. Percentage of Participants With Adverse Events

    An AE is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the study drug. An AE can, therefore, be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.

    Time frame: Through 4 weeks after last dose (approximately Part 2, Week 31)

Other outcomes

  1. Percentage of Participants Experiencing an Adverse Event of Special Interest (AESI)

    An AE is any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AESI can be serious or non-serious.

    Time frame: From Part 1 Day 1 to end of Part 2, including follow-up (Day 197)

  2. Bone Mineral Density Z-Score

    Time frame: Part 1, Day 1, Part 2, Day 1 and Part 2, Week 24

  3. Bone Mineral Density T-Score

    Time frame: Part 1, Day 1, Part 2, Day 1 and Part 2, Week 24

07

Results

Posted Dec 10, 2021

Participant flow

A total of 27 participants were enrolled and treated in the study which was conducted across multiple sites in 9 countries: United States, Canada, Denmark, France, Ireland, Italy, Netherlands, Thailand, and United Kingdom. The study was conducted from 26 June 2018 to 12 November 2020.

Participant flow — Overall Study
MilestoneAG-348
Started27
Completed20
Not completed7
Withdrew: Withdrawal by subject6
Withdrew: Lost to follow-up1

Outcome measures

PrimaryPercentage of Participants Achieving a Reduction in Transfusion Burden in Part 2

Reduction in transfusion burden is defined as a ≥33% reduction in the number of RBC units transfused during the Fixed Dose Period standardized to 24 weeks compared with the historical transfusion burden standardized to 24 weeks (Standardized Control Period). The on-study (Fixed Dose Period) transfusion burden was calculated as the total number of transfused RBC units received in the Fixed Dose Period standardized to 24 weeks.

Time frame:
From Part 2, Day 1 to Part 2 Week 24
Reported as:
Number · percentage of participants
Percentage of Participants Achieving a Reduction in Transfusion Burden in Part 2
percentage of participantsAG-348
Percentage of Participants Achieving a Reduction in Transfusion Burden in Part 237 (19.4 to 57.6)
Statistical analysis
  • AG-348 · Binomial exact test · p = 0.0002 (1-sided P-value)
SecondaryAnnualized Number of RBC Units Transfused During the Study

The annualized total number of RBC units transfused during the entire study (both Part 1 and Part 2) is reported. It was calculated as the total number of RBC units transfused up to the end of Fixed Dose Period divided by the total number of days from the first dose date until the end date of Fixed Dose Period × 52.

Time frame:
Part 1 Day 1 to Part 2 Week 24
Reported as:
Mean · RBC units
Annualized Number of RBC Units Transfused During the Study
RBC unitsAG-348
Annualized Number of RBC Units Transfused During the Study11.52 ± 10.543
SecondaryNumber of Transfusion Episodes in Part 2

This is the number of transfusion episodes in Part 2. The number of transfusion episodes were standardized to 24 weeks. Transfusions received over up to 3 consecutive days were counted as 1 episode.

Time frame:
From Part 2 Day 1 to Part 2 Week 24
Reported as:
Mean · transfusion episodes
Number of Transfusion Episodes in Part 2
transfusion episodesAG-348
Number of Transfusion Episodes in Part 22.88 ± 2.694
SecondaryPercentage of Transfusion-Free Participants in Part 2

Transfusion-free responders were the participants who were transfusion-free in Part 2.

Time frame:
From Part 2 Day 1 to Part 2 Week 24
Reported as:
Number · percentage of participants
Percentage of Transfusion-Free Participants in Part 2
percentage of participantsAG-348
Percentage of Transfusion-Free Participants in Part 222.2 (8.6 to 42.3)
SecondaryPercentage of Participants Achieving Normal Hemoglobin (Hb) Concentrations in Part 2

This is the percentage of participants who achieved hemoglobin (Hb) concentrations in the normal range at least once, 8 weeks or more after a transfusion in Part 2.

Time frame:
From Part 2 Day 1 to Part 2 Week 24
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Normal Hemoglobin (Hb) Concentrations in Part 2
percentage of participantsAG-348
Percentage of Participants Achieving Normal Hemoglobin (Hb) Concentrations in Part 211.1 (2.4 to 29.2)
SecondaryPercentage of Participants With Adverse Events

An AE is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the study drug. An AE can, therefore, be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.

Time frame:
Through 4 weeks after last dose (approximately Part 2, Week 31)
Reported as:
Number · percentage of participants
Percentage of Participants With Adverse Events
percentage of participantsAG-348
Percentage of Participants With Adverse Events100
Other pre-specifiedPercentage of Participants Experiencing an Adverse Event of Special Interest (AESI)

An AE is any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AESI can be serious or non-serious.

Time frame:
From Part 1 Day 1 to end of Part 2, including follow-up (Day 197)

Results for this outcome have not been posted.

Other pre-specifiedBone Mineral Density Z-Score
Time frame:
Part 1, Day 1, Part 2, Day 1 and Part 2, Week 24

Results for this outcome have not been posted.

Other pre-specifiedBone Mineral Density T-Score
Time frame:
Part 1, Day 1, Part 2, Day 1 and Part 2, Week 24

Results for this outcome have not been posted.

Adverse events

Collected over From Part 1 Day 1 to end of Part 2, including follow-up (up to Day 197). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
AG-3480/27 (0%)3/27 (11.1%)27/27 (100%)
Most frequent serious events
Most frequent serious events
EventAG-348
Blood Triglyceride IncreasedInvestigations1/27
Ovarian CystReproductive system and breast disorders1/27
Renal ColicRenal and urinary disorders1/27
Most frequent other events
Showing 10 of 26
Most frequent other events
EventAG-348
HeadacheNervous system disorders10/27
Alanine aminotransferase increasedInvestigations10/27
NauseaGastrointestinal disorders5/27
Aspartate aminotransferase increasedInvestigations5/27
FatigueGeneral disorders5/27
NasopharyngitisInfections and infestations4/27
Upper respiratory tract infectionInfections and infestations4/27
Viral upper respiratory tract infectionInfections and infestations4/27
VomitingGastrointestinal disorders4/27
DyspnoeaRespiratory, thoracic and mediastinal disorders4/27

Baseline characteristics

Full analysis set included all participants who received at least 1 dose of study drug.

Age, Continuous
Age, Continuous(years)AG-348
Mean36.6 ± 13.89
Sex: Female, Male
Sex: Female, Male(Participants)AG-348
Female20
Male7
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)AG-348
Hispanic or Latino0
Not Hispanic or Latino20
Unknown or Not Reported7
Race (NIH/OMB)
Race (NIH/OMB)(Participants)AG-348
American Indian or Alaska Native0
Asian3
Native Hawaiian or Other Pacific Islander0
Black or African American0
White20
More than one race0
Unknown or Not Reported4
08

Study locations

19 sites
  • UCSF Benioff Children's Hospital
    Oakland, California 94609, United States
  • Emory University
    Atlanta, Georgia 30322, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02115, United States
  • Seattle Cancer Care Alliance
    Seattle, Washington 98109, United States
  • Toronto General Hospital, University Health Network
    Toronto, M5G 2C4, Canada
  • University of Copenhagen, Herlev Hospital
    Herlev, 2730, Denmark
  • Hopital Universitaire Henri Mondor
    Créteil, 94010, France
  • Hôpital de la Timone
    Marseille, Cedex 5, 13385, France
  • St James's Hospital Department of Haematology
    Dublin, Ireland
  • Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
    Milano, 20122, Italy
  • AORN Cardarelli
    Napoli, 80131, Italy
  • Ospedale Galliera
    Napoli, 80131, Italy
  • AOU Policlinico, Università della Campania "Luigi Vanvitelli"
    Napoli, 80138, Italy
  • Universitair Medisch Centrum Utrecht
    Utrecht, 3584, Netherlands
  • Department of Paediatrics and Thalassaemia Center, Faculty of Medicine Siriraj Hospital, Mahidol University
    Bangkok, 10700, Thailand
  • Addenbrooke's Hospital
    Cambridge, CB2 0QQ, United Kingdom
  • Imperial College Healthcare NHS Trust, Hammersmith Hospital
    London, W12 0NN, United Kingdom
  • University College London
    London, WC1E 6BT, United Kingdom
  • Manchester Royal Infirmary
    Manchester, M13 9WL, United Kingdom
09

References and documents

Publications

  • Glenthoj A, van Beers EJ, Al-Samkari H, Viprakasit V, Kuo KHM, Galacteros F, Chonat S, Porter J, Zagadailov E, Xu R, Oluyadi A, Hawkins P, Gheuens S, Beynon V, Barcellini W; ACTIVATE-T investigators. Mitapivat in adult patients with pyruvate kinase deficiency receiving regular transfusions (ACTIVATE-T): a multicentre, open-label, single-arm, phase 3 trial. Lancet Haematol. 2022 Oct;9(10):e724-e732. doi: 10.1016/S2352-3026(22)00214-9. Epub 2022 Aug 18. PubMed 35988546 ↗
  • Rab MAE, Van Oirschot BA, Kosinski PA, Hixon J, Johnson K, Chubukov V, Dang L, Pasterkamp G, Van Straaten S, Van Solinge WW, Van Beers EJ, Kung C, Van Wijk R. AG-348 (Mitapivat), an allosteric activator of red blood cell pyruvate kinase, increases enzymatic activity, protein stability, and ATP levels over a broad range of PKLR genotypes. Haematologica. 2021 Jan 1;106(1):238-249. doi: 10.3324/haematol.2019.238865. PubMed 31974203 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2018 to primary completion in Nov 2020, 28 months.

Results were first posted in Dec 2021, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 26, 2018
First posted
Jun 18, 2018
StartActual
Jun 26, 2018
Primary completionActual
Nov 12, 2020
CompletionActual
Nov 12, 2020
Results first posted
Dec 10, 2021
Last update
Jan 4, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 4, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03559699
Responsible party
Sponsor
First posted
Jun 18, 2018
Start date
Jun 26, 2018
Primary completion
Nov 12, 2020
Completion
Nov 12, 2020
Results posted
Dec 10, 2021
Last update
Jan 4, 2022

Study contacts

Medical Affairs
study chair · Agios Pharmaceuticals, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Mitapivat

Start the discussion